Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Dexamethasone (DEX) is the first drug to show life-saving efficacy in patients with severe
coronavirus disease 2019 (COVID-19), while DEX is associated with serious adverse …

The main protease (M pro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral …

Emerging SARS-CoV-2 variants continue to cause waves of new infections globally.
Developing effective antivirals against SARS-CoV-2 and its variants is an urgent task. The …

The emergence of SARS-CoV-2 variants and potentially other highly pathogenic
sarbecoviruses in the future highlights the need for pan-sarbecovirus vaccines. Here, we …

Researchers are constantly looking to find new techniques of virus detection that are
sensitive, cost-effective, and accurate. Additionally, they can be used as a point-of-care …

Abstract Emerging SARS-CoV-2 variants, particularly the Omicron variant and its
sublineages, continually threaten the global public health. Small molecule antivirals are an …

In recent years, highly pathogenic avian influenza H5 subtype (HPAI H5) viruses have been
prevalent around the world in both avian and mammalian species, causing serious …

Protein degradation technology has progressed dramatically since 2001 when proteolysis
targeting chimera (PROTAC) was first reported. Various of distinctive degradation …